Lustracept (MF-associated anemia)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-14 — Highlights From EHA 2026: The Latest Findings in Myeloproliferative Neoplasms: EHA 2026 readout of phase 2 INDEPENDENCE trial: lustracept missed its primary endpoint in advanced MF-associated anemia but significantly improved all secondary endpoints (trial-early). (novelty: 3)
Open questions
Related
Contributing findings
Highlights From EHA 2026: The Latest Findings in Myeloproliferative Neoplasms
14-aug-2026
novelty 3
per-area 3
strengthens